PRRT

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Stony Brook University, University, Adenocarcinoma, PRRT, Patient, Mayo Clinic, Sale, Bristol Myers Squibb, Society, IND, European Journal, Therapy, SPECT, Melanoma, Research, MC1R, Fortis Healthcare, SNMMI, Cohort, Trial of the century, Radiopharmaceutical, Cancer, Nivolumab, Safety, CATX, PSMA, Food, LNTH, BMY, IIT, Prostate cancer, Nuclear medicine, EANM, NETS, Institute of technology, Diagnosis, Glomus tumor, PET, Prostate, Small business, Bangladesh Technical Education Board, Molecular imaging, Pharmaceutical industry

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.

Key Points: 
  • SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.
  • “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics' CEO.
  • Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third quarter 2024.
  • In January 2024, Perspective Therapeutics entered into strategic agreements with Lantheus Holdings, Inc. and its affiliates (“Lantheus”) (NASDAQ: LNTH).

RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM in gastroenteropancreatic neuroendocrine tumors First Targeted Alpha Therapy to receive a Breakthrough Therapy Designation

Retrieved on: 
Monday, February 12, 2024
Oncology, Health, FDA, Clinical Trials, Radiology, Pharmaceutical, Toxicity, BTD, MD, GEP-NET, News, Breakthrough therapy, Breakthrough, Safety, Patient, RECIST, Alpha, PRRT, Pharmaceutical industry

AlphaMedixTM is a Targeted Alpha Therapy currently in Phase 2 clinical development, which consists of an SSTR-targeting peptide complex radiolabeled with lead-212 (212Pb) that serves as an in vivo generator of alpha particles.

Key Points: 
  • AlphaMedixTM is a Targeted Alpha Therapy currently in Phase 2 clinical development, which consists of an SSTR-targeting peptide complex radiolabeled with lead-212 (212Pb) that serves as an in vivo generator of alpha particles.
  • AlphaMedixTM is the first Targeted Alpha Therapy to receive Breakthrough Therapy Designation.
  • “The FDA's Breakthrough Therapy Designation underscores AlphaMedixTM potential as an innovative treatment that could redefine how patients with neurendocrine tumors are treated.
  • “Receiving FDA Breakthrough Therapy Designation for AlphaMedixTM is a great achievement for everyone involved and confirms the strong interest of the medical community for Targeted Alpha Therapies with lead-212.

Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors

Retrieved on: 
Thursday, December 7, 2023
University, SSTR2, Neoplasm, Perspective, TAT, NETS, Therapy, Standard of care, PRRT, Patient, CATX, Safety, DOTATATE, Glomus tumor, Pharmaceutical industry

The patients being enrolled in the study have either progressed or relapsed after previous therapies, including currently approved peptide receptor radionuclide therapies (“PRRT”).

Key Points: 
  • The patients being enrolled in the study have either progressed or relapsed after previous therapies, including currently approved peptide receptor radionuclide therapies (“PRRT”).
  • The trial is a single-center, open-label study of [212Pb]VMT-α-NET that is designed to explore safety and efficacy when pre-treatment dose planning is aided by imaging with [203Pb]VMT-α-NET using quantitative SPECT/CT imaging.
  • “We are delighted that this innovative investigator-initiated study has commenced in refractory and relapsed neuroendocrine tumor patients,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics.
  • We are excited by this collaboration, and we look forward to the Iowa team presenting preliminary findings in 2024.”

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 14, 2023
Lung, Lutetium (177Lu) oxodotreotide, Seed, EANM, Patient, Clinical study report, Research, Radiation therapy, Marketing, Stony Brook University, UPMC Hillman Cancer Center, Medullary thyroid cancer, Growth, Congress, University, Fortis Healthcare, Pelvic exenteration, Radiation, PRRT, Toxicity, IND, GEP-NET, MTC, Melanoma, Perspective, CATX, Communication, NET, Society, ASTRO, Therapy, NETS, Wilfrid Sellars, Brain, Biology, Nuclear Medicine and Biology, Glomus tumor, NYSE, PET/CT, SPECT/CT, Clinical trial, MC1R, Prostate cancer, NIH, Survival, UPMC, GEP, Rare-earth element, Medical imaging, Pharmaceutical industry, Medical device, Cryptocurrency, Nuclear medicine, Brachytherapy

Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.

Key Points: 
  • Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.
  • Third quarter 2023 revenue was the highest since the second quarter of 2022, with a return to growth over the third quarter of 2022.
  • Total operating expenses for the quarter ended September 30, 2023 were $11.3 million, compared to $4.6 million for the same period in 2022, an increase of 144%.
  • Cash and cash equivalents as of September 30, 2023 was $18.0 million as compared to $43.9 million on December 31, 2022.

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of [(212)Pb]VMT-α-NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Retrieved on: 
Wednesday, November 8, 2023
Radiation therapy, Standard of care, DOTATATE, NYSE, Washington University in St. Louis, CATX, European Association of Nuclear Medicine, Mallinckrodt Institute of Radiology, PRRT, Glomus tumor, Tissue, Washington University School of Medicine, SSTR2, European Association for the Study of the Liver, NETS, TAT, Safety, Fast track (FDA), Therapy, Patient, Pharmaceutical industry, Radiology

The trial is a multi-center, open-label dose escalation, dose expansion study of [212Pb]VMT-α-NET in patients who have not received prior peptide receptor radionuclide therapy (PRRT).

Key Points: 
  • The trial is a multi-center, open-label dose escalation, dose expansion study of [212Pb]VMT-α-NET in patients who have not received prior peptide receptor radionuclide therapy (PRRT).
  • “We are proud of our team’s commitment and progress in bringing our radionuclide therapy to patients suffering from these difficult-to-treat neuroendocrine tumors,” said Thijs Spoor, Chief Executive Officer of Perspective Therapeutics.
  • “The development of Perspective’s [212Pb]VMT-α-NET targeted alpha particle therapy is an important next step in the evolution of treatments for SSTR2-expressing tumors.
  • We are excited to participate in the trial.”
    “We are excited about our collaboration with investigators from top-tier research centers who are evaluating [212Pb]VMT-α-NET in patients with intractable SSTR2-expressing neuroendocrine tumors,” said Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics.

Next Generation Drug Conjugates Market to Soar with Over 20% CAGR: Revolutionizing Rare Disease Treatment and Oncology Therapies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 17, 2023
Pharmaceutical, Health, Oncology, Ligand, Cancer, Lipid, Antibody, USFDA, U.S.–Afghanistan Strategic Partnership Agreement, Lutetium (177Lu) oxodotreotide, LICA, Oligonucleotide, Traction, Success, Radionuclide, USD, Therapy, Janssen, Generic drug, Novartis, SMDC, FDA, AstraZeneca, Peptide, Growth, Brown sugar, Rare disease, Region, Rare, Clinical trial, PRRT, Spacecraft, N-Acetylgalactosamine, Alnylam Pharmaceuticals, Patient, Fine chemical, Pharmaceutical industry, Vaccine, Lutetium (177Lu) vipivotide tetraxetan

This growing burden of rare diseases has driven the search for alternative therapies, and next generation drug conjugates have emerged as a viable option.

Key Points: 
  • This growing burden of rare diseases has driven the search for alternative therapies, and next generation drug conjugates have emerged as a viable option.
  • Advantages Over Antibody Drug Conjugates (ADCs): Next generation drug conjugates share similarities with antibody drug conjugates (ADCs) but offer advantages in terms of clinical efficacy and stability.
  • Types of Next Generation Drug Conjugates: Various types of next generation drug conjugates have emerged, including peptide drug conjugates, peptide receptor radionuclide therapy (peptide radionuclide conjugates), GalNac conjugates, peptide oligonucleotide conjugates, si-RNA conjugates, small molecule-drug conjugates (SMDC), ligand-conjugated antisense medicine (LICA), and peptide-conjugated phosphorodiamidate morpholino oligomers (PPMO).
  • Peptide Drug Conjugates: Peptide drug conjugates have emerged as a promising alternative to antibody drug conjugates (ADCs).

Molecular Targeting Technologies, Inc. to Present EvaThera, Long-Acting Peptide Receptor Radionuclide Therapy Platform, at BioFuture™ 2023

Retrieved on: 
Thursday, October 5, 2023
Biotechnology, General Health, Pharmaceutical, Health, Cancer, Biomarker, Doctor of Philosophy, Lotte New York Palace Hotel, Therapy, Radiation, Peptide, PRRT, Pharmaceutical industry

Molecular Targeting Technologies, Inc. (MTTI), is presenting at BioFuture 2023 on Thursday 2:45 PM, Oct 5th, at Lotte New York Palace hotel.

Key Points: 
  • Molecular Targeting Technologies, Inc. (MTTI), is presenting at BioFuture 2023 on Thursday 2:45 PM, Oct 5th, at Lotte New York Palace hotel.
  • This year, registered, in-person attendees can view MTTI’s presentation live, and get advance access to a recorded version beginning September 1, five weeks prior to the actual event.
  • Jianwei Xu, PhD, Chief Business Officer will introduce MTTI’s EvaThera, the first long-acting, targeted peptide receptor radionuclide therapy (PRRT) platform.
  • This class of therapeutics has seen explosive growth since 2018, projected to continue at 34% CAGR over the next decade.

Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Tuesday, September 12, 2023
Pheochromocytoma, DOTATATE, NETS, MBBS, EANM, TAT, Thyroid cancer, Quality of life, DNB, Nuclear medicine, Paraganglioma, PET-CT, Șaeș, Non-small-cell lung cancer, MDS, Hair, Targeted molecular therapy for neuroblastoma, CATX, Patient, Standard of care, Syndrome, Molina Healthcare, FMRI, European Association for the Study of the Liver, Therapy, NYSE, PRRT, Meningioma, Safety, Fatigue, Pharmaceutical industry

Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.

Key Points: 
  • Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.
  • The results were presented at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), held in Vienna, Austria, from September 9-13, 2023.
  • Improvements in patients’ symptoms and quality of life trended strongly positive with consecutive [212Pb]VMT-α-NET doses.
  • We will continue to monitor patients’ progress, and we look forward to providing a more extensive data readout in the upcoming quarters.”

Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore Receive HSA Approval for Clinical Trial Authorization for EBTATE® in Nasopharyngeal Cancer

Retrieved on: 
Wednesday, August 2, 2023
Research, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, General Health, Science, Oncology, NICS, Nephrotoxicity, Prevalence, GBM, Half-life, National University of Singapore, National university, Glomus tumor, Safety, Hope, CTA, Multimedia, NSCLC, Lung cancer, HTC, Glioblastoma, Death, Carcinoma, Serum albumin, MD, NCIS, Patient, PRRT, Outline of health sciences, Cancer, SSTR2, Neoplasm, NPC, MTCS, Health Sciences Authority, HSA, NUS, Pharmaceutical industry, Medical imaging

Molecular Targeting Technologies, Inc. (MTTI), and its wholly owned subsidiary, Molecular Theranostic Center of Singapore (MTCS), announced the approval of a Clinical Trial Authorization (CTA) application by the Health Sciences Authority (HSA) of Singapore.

Key Points: 
  • Molecular Targeting Technologies, Inc. (MTTI), and its wholly owned subsidiary, Molecular Theranostic Center of Singapore (MTCS), announced the approval of a Clinical Trial Authorization (CTA) application by the Health Sciences Authority (HSA) of Singapore.
  • View the full release here: https://www.businesswire.com/news/home/20230802243597/en/
    Somatostatin receptor 2 (SSTR2) is found in 81% of primary, recurrent, and metastatic NPC patients.
  • A recent three-year clinical trial follow-up* showed EBTATE was effective at controlling tumor and well tolerated without serious adverse events or nephrotoxicity.
  • MTTI’s products include: EBTATE (neuroendocrine tumors (“NET”); Hürthle thyroid cancer (HTC), and nasopharyngeal cancer (NPC); EBRGD for non-small cell lung cancer (NSCLC) and glioblastoma (GBM).

MTTI Highlights Promising One-Year Follow-Up on EBTATE Treatment of Neuroendocrine Cancer Patients Without Amino Acid Infusion

Retrieved on: 
Wednesday, June 21, 2023
Oncology, Health, General Health, Radiology, Clinical Trials, Pharmaceutical, Biotechnology, GFR, Hyperkalemia, Carcinoma, Radiation, Nephrotoxicity, Biodistribution, Blood urea nitrogen, Dosimetry, Half-life, Creatinine, Overalls, Quality of life, Glomerular filtration rate, NET, Dicarboxylic acid, Vomiting, Serum albumin, MD, Patient, Cancer, Kidney, Creatine, Nausea, BUN, PRRT, Phosphorus, Dietary supplement, Safety

Molecular Targeting Technologies, Inc. (MTTI) announced promising results from a 1-year follow-up on EBTATE (2 cycles, 3.7 GBq/cycle) treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) without amino acid pretreatment.

Key Points: 
  • Molecular Targeting Technologies, Inc. (MTTI) announced promising results from a 1-year follow-up on EBTATE (2 cycles, 3.7 GBq/cycle) treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) without amino acid pretreatment.
  • A 4-hour long amino acid cocktail infusion reduces renal absorbed radiation dose, with significant side effects like nausea, vomiting and hyperkalemia.
  • EBTATE administration appears to be safe without amino acid infusion.”
    Chris Pak, President & CEO of MTTI commented, “Amino acid infusion impacts quality of life, access to care, patient compliance to treatment and overall treatment costs.
  • Evaluation of Safety, Biodistribution and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE (EBTATE) with and without Amino Acid Infusion.